Abstract
The emergence of infections caused by multi-drug resistant (MDR) pathogens pose a major burden to modern healthcare. Exacerbating this issue is the substantial decline in development of new classes of antibiotics by pharmaceutical companies. This has led to renewed interest in the therapeutic potential of natural anti-infective agents such as host defense peptides (HDPs). The broad antimicrobial and immunomodulatory activities of HDPs and their synthetic derivatives, coupled with the fact that they do not readily induce microbial resistance, makes them extremely valuable leads in the development of new treatment strategies for MDR infections. This review examines our knowledge of the mechanisms behind multi-drug resistance as well as the properties of HDPs and their therapeutic potential, especially in the case of MDR infections. Challenges to their development as new therapeutics are also discussed.
Keywords: Host-defense peptide, multi-drug resistant bacteria, immunomodulatory, immunity, infection, therapeutic, chemoattractant, inflammation, penicillin, endotoxin neutralization
Current Pharmaceutical Design
Title: Therapeutic Potential of Host Defense Peptides in Antibiotic-resistant Infections
Volume: 18 Issue: 6
Author(s): Nicole J. Afacan, Amy T.Y. Yeung, Olga M. Pena and Robert E.W. Hancock
Affiliation:
Keywords: Host-defense peptide, multi-drug resistant bacteria, immunomodulatory, immunity, infection, therapeutic, chemoattractant, inflammation, penicillin, endotoxin neutralization
Abstract: The emergence of infections caused by multi-drug resistant (MDR) pathogens pose a major burden to modern healthcare. Exacerbating this issue is the substantial decline in development of new classes of antibiotics by pharmaceutical companies. This has led to renewed interest in the therapeutic potential of natural anti-infective agents such as host defense peptides (HDPs). The broad antimicrobial and immunomodulatory activities of HDPs and their synthetic derivatives, coupled with the fact that they do not readily induce microbial resistance, makes them extremely valuable leads in the development of new treatment strategies for MDR infections. This review examines our knowledge of the mechanisms behind multi-drug resistance as well as the properties of HDPs and their therapeutic potential, especially in the case of MDR infections. Challenges to their development as new therapeutics are also discussed.
Export Options
About this article
Cite this article as:
J. Afacan Nicole, T.Y. Yeung Amy, M. Pena Olga and E.W. Hancock Robert, Therapeutic Potential of Host Defense Peptides in Antibiotic-resistant Infections, Current Pharmaceutical Design 2012; 18 (6) . https://dx.doi.org/10.2174/138161212799277617
DOI https://dx.doi.org/10.2174/138161212799277617 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PEGylated Lipid Nanocapsules with Improved Drug Encapsulation and Controlled Release Properties
Current Topics in Medicinal Chemistry A Novel Role of the STAT3 Pathway in Brain Inflammation-induced Human Neural Progenitor Cell Differentiation
Current Molecular Medicine Advances and Application of DNA-functionalized Nanoparticles
Current Medicinal Chemistry Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry Comparative Study and Classification of Human Chemokine Receptors
Current Proteomics Silver Nanoparticles: Synthesis, Characterization and their Application as a Sustainable Catalyst for Organic Transformations
Current Organic Chemistry Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
Current Radiopharmaceuticals Ionic Liquids, Microextraction Methods and Capillary Electrophoresis in Biomedical Research
Current Pharmaceutical Analysis Bronchiolar Disorders In Childhood
Current Pediatric Reviews Monoclonal Antibodies: A Prospective and Retrospective View
Current Medicinal Chemistry Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets PEO-PPO-PEO/Poly(DL-lactide-co-caprolactone) Nanoparticles as Carriers for SN-38: Design, Optimization and Nano-Bio Interface Interactions
Current Drug Delivery Library of Synthetic Compounds Based on Pyrazole Unit: Design and Screening Against Breast and Colorectal Cancer
Letters in Drug Design & Discovery Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Protein-protein Interfaces Integrated into Interaction Networks: Implications on Drug Design
Current Pharmaceutical Design Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design DNA Methylation Markers in Lung Cancer
Current Genomics